Comparing Precision Therapy to Standard Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome in Older Adults
Led by University Hospital, Akershus · Updated on 2021-08-27
36
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether precision therapy guided by a Clinical Tumour Board is more cost-effective and beneficial compared to standard treatment for elderly patients with acute myeloid leukemia AML and high-risk myelodysplastic syndrome MDS. This phase II, randomized clinical trial focuses on patients aged 60 and older who are not eligible for intensive chemotherapy or stem cell transplant. Precision therapy is tailored based on genetic changes found in the tumor using next generation sequencing NGS.
Participants first receive two 28-day cycles of standard treatment, which for AML includes azacitidine plus venetoclax if available, or azacitidine alone for MDS patients. During this initial treatment, bone marrow samples are analyzed by the Tumour Board to determine suitable targeted therapies for the precision therapy group. After initial treatment, patients without disease progression are randomized in a 21 ratio to either continue standard therapy or receive precision therapy combined with standard treatment.
Throughout the 4 to 5 years of follow-up, patients undergo regular assessments including bone marrow evaluations, genomic profiling, and monitoring of treatment response, adverse events, quality of life, and healthcare costs. The study measures cost-effectiveness as the primary outcome, alongside survival, toxicity, transfusion dependence, and progression. Safety and efficacy are carefully tracked to understand the impact of personalized precision therapy in this elderly population.
CONDITIONS
Brief Title
Precision Therapy Versus Standard Therapy in AML and MDS in Elderly
Research Team
A
Anders Erik Astrup Dahm, MD,PHD
A
Abrar Zaheer Quazi, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients diagnosed with AML or related precursor neoplasms according to WHO 2016 classification (excluding acute promyelocytic leukemia) including secondary and therapy-related AML, or acute leukemias of ambiguous lineage, or high-risk myelodysplastic syndrome with IPSS-R > 4.5
Age 60 years or older
Not eligible for intensive chemotherapy or allogeneic stem cell transplantation
White blood cell count (WBC) ≤ 25 x10^9/L (hydroxyurea allowed up to 14 days before treatment)
Adequate kidney and liver function unless disease-related
WHO performance status 0-1-2 if age ≥ 75, or 0-1-2-3 if age 60-74
Life expectancy greater than 3 months
Signed informed consent
Male participants who are sexually active must agree to use condoms from study start until 90 days after last dose and refrain from sperm donation during this period
You will not qualify if you...
Acute promyelocytic leukemia
AML patients with favorable cytogenetic or genetic changes who are fit for intensive chemotherapy
Previous treatment for AML or MDS including investigational agents
Inability to obtain bone marrow sample for sequencing (dry tap)
Previous or concurrent cancer unless successfully treated with curative intent at least 6 months prior
Blast crisis of chronic myeloid leukemia
Severe or uncontrolled medical conditions such as uncontrolled diabetes, infection, hypertension, or pulmonary disease
Cardiac dysfunction including unstable angina, NYHA Class 2 or higher, or unstable arrhythmias
History of non-compliance or unreliability with medical regimens
Dementia, mental impairment, or psychiatric disorder preventing informed consent
Inability to understand written informed consent
Current chemotherapy, radiation, or immunotherapy other than hydroxyurea
Known HIV positive status
Known hepatitis B or C infection unless viral load undetectable within 3 months
Use of strong or moderate CYP3A inducers within 7 days before venetoclax treatment
Malabsorption or other condition preventing oral drug intake
WHO performance status > 2 if age ≥ 75, or > 3 if age 60-74
Disease progression after initial treatment
Eligibility for allogeneic stem cell transplantation after initial treatment
Additional drug-specific exclusions based on product characteristics at randomization
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Initial Standard Therapy
Duration - Approximately 8 weeks
Participants receive two initial 28-day cycles of standard therapy. During this period, bone marrow samples are taken for genomic profiling to guide subsequent precision therapy decisions.
Visits throughout two 28-day treatment cycles
Randomization and Treatment
Duration - Variable, ongoing treatment based on assigned group
Participants without disease progression are randomized to either continue standard therapy or receive precision therapy determined by a Clinical Tumour Board based on genomic profiling. Precision therapy includes standard therapy plus targeted treatments as decided by the Tumour Board.
Regular visits according to assigned treatment schedule
Follow-up and Monitoring
Duration - Up to 4-5 years
Participants are monitored long-term for treatment outcomes including survival, adverse events, and disease progression.
Periodic visits for assessment and monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Long-Term Follow-Up Study Monitoring Participants Previously Treated with TScan TCR-T Cell Therapies for AML, ALL, or MDS
Phase 1 Study of CG009301 Injection for Adults with Relapsed or Refractory Blood Cancers
Evaluating Safety, Dosage, and Effectiveness in Leukemia and Related Disorders
Study of Chidamide and Azacitidine Treatment for Adults with MRD-Positive Acute Myeloid Leukemia After Stem Cell Transplant
Phase 1 Study of Oral Tetrahydrouridine and Decitabine for Treating Relapsed or Refractory Myelodysplastic Syndromes
Evaluating Selinexor with Azacitidine and Venetoclax for Adults with Untreated Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy
Phase I Study Evaluating Safety and Effectiveness of STI-8591 for Adults with Advanced Acute Myeloid Leukemia
Evaluating Cobicistat-Boosted Venetoclax with Azacitidine in Adults with Newly Diagnosed AML Not Suitable for Intensive Chemotherapy
Evaluating Allogeneic Hematopoietic Stem Cell Transplantation
for Patients with GATA2 Mutations or MonoMAC Syndrome
Using Different Donor Types and Conditioning Regimens
Assessment of Geriatric Evaluations and Physiologic Age Impact on Outcomes in Newly Diagnosed AML Patients Over 50
Monitoring Measurable Residual Disease Using Digital PCR to Predict Relapse After Stem Cell Transplant in Leukemia and Related Blood Disorders
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Pierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg...
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.